Kardigan filed for a U.S. IPO while positioning a late-stage cardiovascular precision medicine pipeline with no approved options in several targeted niches. The company plans to use proceeds to advance three programs: danicamtiv for genetic dilated cardiomyopathy, ataciguat for calcific aortic valve stenosis, and tonlamarsen for severe acute hypertension via hepatic angiotensinogen targeting. Kardigan’s structure reflects an “option to win” strategy in cardiology where efficacy benchmarks and endpoints are tightly defined, but unmet-market segments remain. The filing also highlights experience recycled from MyoKardia leadership, including prior work tied to mavacamten. With biotech reopening to public-market fundraising after a quieter stretch, the Kardigan debut is another test of whether investors are underwriting late-stage data quality and clearer regulatory paths in cardiometabolic and cardiovascular disease.